Is ADC Therapeutics SA (ADCT) undervalued? · rev $70.8M
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
This page asks whether ADC Therapeutics SA (ADCT) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported ADCT revenue for 2024-12-31 was $70.8M. Net income was -$157.8M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. ADCT currently screens at market cap $141.2M.
ADCT currently screens at market cap $141.2M. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new ADCT 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare ADCT to the stock page model before you treat a low multiple as a gift.
Not investment advice.